Abstract
This international symposium was hold in Cádiz in November 2002. In the first conference, a classification of anticancer drugs including all the new compounds was proposed. The role of cholino-kinase in oncogenesis was revised, as well as the possibility to use this model in the development of new drugs. The first group of conferences was finished with a speech about how we are investigating with new drugs, considering the limitations of our traditional paradigm. The second group of conferences included a revision of different drugs: monoclonal antibodies, gefitinib, imatinib and Cox-2 inhibitors. The speakers commented on the results of clinical trials and the future investigation with these drugs. Finally, the third block included a revision a techniques in molecular oncology and a speech about the kind of information that we are achieving through the use of these techniques.
| Original language | Spanish |
|---|---|
| Pages (from-to) | 98-110 |
| Number of pages | 13 |
| Journal | Clinical and Translational Oncology |
| Volume | 5 |
| Issue number | 2 |
| State | Published - Mar 2003 |
Fingerprint
Keywords
- Cholino-kinase
- Gefitinib
- Monoclonal imatinib
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
X Curso internacional de avances en Oncología : Investigación y nuevos fármacos. / Arranz, Enrique Espinosa; Hidalgo, Manuel; Sanjuán, Juan Carlos Lacal; Reyes, Félix; De Paredes, M. Luisa García; Picó, César; Abellón, Rosario Perona; Polyak, K.
In: Clinical and Translational Oncology, Vol. 5, No. 2, 03.2003, p. 98-110.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - X Curso internacional de avances en Oncología
T2 - Investigación y nuevos fármacos
AU - Arranz, Enrique Espinosa
AU - Hidalgo, Manuel
AU - Sanjuán, Juan Carlos Lacal
AU - Reyes, Félix
AU - De Paredes, M. Luisa García
AU - Picó, César
AU - Abellón, Rosario Perona
AU - Polyak, K.
PY - 2003/3
Y1 - 2003/3
N2 - This international symposium was hold in Cádiz in November 2002. In the first conference, a classification of anticancer drugs including all the new compounds was proposed. The role of cholino-kinase in oncogenesis was revised, as well as the possibility to use this model in the development of new drugs. The first group of conferences was finished with a speech about how we are investigating with new drugs, considering the limitations of our traditional paradigm. The second group of conferences included a revision of different drugs: monoclonal antibodies, gefitinib, imatinib and Cox-2 inhibitors. The speakers commented on the results of clinical trials and the future investigation with these drugs. Finally, the third block included a revision a techniques in molecular oncology and a speech about the kind of information that we are achieving through the use of these techniques.
AB - This international symposium was hold in Cádiz in November 2002. In the first conference, a classification of anticancer drugs including all the new compounds was proposed. The role of cholino-kinase in oncogenesis was revised, as well as the possibility to use this model in the development of new drugs. The first group of conferences was finished with a speech about how we are investigating with new drugs, considering the limitations of our traditional paradigm. The second group of conferences included a revision of different drugs: monoclonal antibodies, gefitinib, imatinib and Cox-2 inhibitors. The speakers commented on the results of clinical trials and the future investigation with these drugs. Finally, the third block included a revision a techniques in molecular oncology and a speech about the kind of information that we are achieving through the use of these techniques.
KW - Cholino-kinase
KW - Gefitinib
KW - Monoclonal imatinib
UR - http://www.scopus.com/inward/record.url?scp=84873451934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873451934&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84873451934
VL - 5
SP - 98
EP - 110
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
SN - 1699-048X
IS - 2
ER -